



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: N° I/S/10-26-40

Spurious/Falsified Nasomet Aqueous Nasal Spray (Mometasone Furoate 50 mcg/spray), Batch No. FW-099

Date: 19th October, 2026

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

Central Drugs Laboratory, Karachi declared the following sample as **Spurious/Falsified** under Section 3(z-b) (ii) & 3(z-b) (ii) of the Drugs Act, 1976 The sample was referred to CDL, Karachi, by the Area Federal Inspector of Drugs, Karachi, on the grounds that it was suspected to be spurious. M/s Sante Sante (Private) Limited, A-97, SITE Superhighway, Karachi, has disowned the sample, stating that it does not belong to or originate from the said manufacturer.

S#	Product Name	Batch	Manufacturer (as per label)	Test Result
1	Nasomet Aqueous Nasal Spray Each Spray Contains: Mometasone Furoate 50 mcg (Reg # 108661)	FW-099	Purported to be manufactured by: M/s Sante (Private) Limited (DML # 000702) A-97, SITE Superhighway, Karachi.	Declared Spurious / falsified (Mometasone furoate not identified)

Risk Statement:

Use of this product may result in treatment failure due to the absence of the declared active ingredient and may pose potential risks to patient safety.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).



DRAP, Islamabad

+ 92 051 9255969

gsms@dra.gov.pk



DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج



DRAP, Islamabad



+ 92 051 9255969



gsms@dra.gov.pk